
Jon Giles
Articles
-
Sep 4, 2024 |
acrjournals.onlinelibrary.wiley.com | Jane Kang |Howard F. Andrews |Jon Giles |Katherine P Liao
Supporting Information Filename Description acr25424-sup-0001-Disclosureform.pdfPDF document, 840.5 KB Disclosure Form acr25424-sup-0002-Supinfo.zipZip archive, 94.8 KB Appendix S1: Supporting Information
-
Jun 24, 2024 |
arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more
The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).
-
Jun 24, 2024 |
arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more
The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).
-
Jun 24, 2024 |
arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more
The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).
-
Nov 16, 2023 |
medscape.com | Philip Mease |Jon Giles
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. My Alerts You have already selected for My Alerts Add Other Topics Click the topic below to receive emails when new articles are available. Add You've successfully added to your alerts. You will receive email when new content is published.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →